Moderna, Inc. (MRNA) Competitors & Peers
The 5 largest companies in the same industry as Moderna, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $505.26 | P/E 29.4RSI 40Cap 128.3 B |
| REGN | Peer | $784.29 | P/E 19.4RSI 48Cap 80.8 B |
| ARGX | Peer | $994.01 | P/E 38.0RSI 53Cap 62.1 B |
| RVMD | Peer | $189.77 | RSI 35Cap 40.8 B |
| CSLLY | Peer | $31.01 | P/E 18.2RSI 71Cap 60.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- TKPHFSupplier
Own 10-K customer-concentration disclosure: TakedaPharmaceuticalCompany = 10% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - PSNLSupplier
Own 10-K customer-concentration disclosure: ModernaInc = 28% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - AZNSupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 34% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- MRKPartner
Merck-Moderna individualized neoantigen therapy (mRNA-4157/V940) + Keytruda combo in Phase III melanoma.
Model-inferred, unverified — treat as a lead, not evidence - ARESupplier
Alexandria leases Moderna's R&D + manufacturing space in Cambridge MA.
Model-inferred, unverified — treat as a lead, not evidence - ILMNSupplier
Moderna uses Illumina sequencing for vaccine + immune-response profiling.
Model-inferred, unverified — treat as a lead, not evidence